Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director · CEO | August 16, 2024 | August 20, 2024 |
| AEON Biopharma, Inc.AEON · Entity 7859 | CHIEF FINANCIAL OFFICER | April 02, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date August 16, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,636 |
Reported balance
After 2024-08-16 transaction · row 1
1 source rowRow 1 · 2024-08-16 · Grant · Acquired 5,000 · Balance 100,636 F1: Represents shares of common stock acquired under the Issuer's 2017 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock acquired under the Issuer's 2017 Employee Stock Purchase Plan.
AEON Biopharma, Inc.
Report date April 02, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 754,717 |
Reported balance
After 2026-04-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 754,717 · Balance 754,717 F1: Represents an award of restricted stock units granted on April 1, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units granted on April 1, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2026 Filed Apr 3, 2026 22:22 UTC | AEON Biopharma, Inc. AEON · Entity 7859 | GrantClass A Common Stock | 754,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-039697 · tm2611116-2_4seq1.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 754,717 F1 · security: Represents an award of restricted stock units granted on April 1, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. F1 · price: Represents an award of restricted stock units granted on April 1, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:05 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantCommon Stock | 5,000 | $3.67 | $18,350.00 |
DisclosureSEC source: 0000950170-24-099074 · ownership.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,636 F1 · kind: Represents shares of common stock acquired under the Issuer's 2017 Employee Stock Purchase Plan. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 20:26 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionPerformance Restricted Stock Unit (PRSU) · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-046936 · ownership.xml · derivative · entry 3 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the PRSU 50% of the total shares underlying the PRSU vest on the achievement of a performance-based milestone, and 50% vest on the first anniversary of the achievement of such milestone. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 20:26 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 6,088 | $4.51 | $27,456.88 |
DisclosureSEC source: 0000950170-24-046936 · ownership.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,636 F2 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of PRSUs. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 20:26 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-046936 · ownership.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:43 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0000950170-24-027243 · ownership.xml · derivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.expiration_date: The common shares reported on this Form 4 were purchased in a registered direct offering (the "RDO") at a price of $4.585, for an aggregate purchase price of $45,850 pursuant to a Securities Purchase Agreement (the "SPA") dated February 28, 2024. The SPA also provides for a concurrent private placement of warrants to purchase common shares (the "Private Placement Warrants") . The Private Placement Warrants are exercisable immediately upon issuance until the earlier of (x) three and one-half years after the date of issuance, and (y) 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA in a Day 74 Letter or equivalent correspondence. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:43 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | PurchaseCommon Stock | 10,000 | $4.59 | $45,850.00 |
DisclosureSEC source: 0000950170-24-027243 · ownership.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,724 F1 · shares: The common shares reported on this Form 4 were purchased in a registered direct offering (the "RDO") at a price of $4.585, for an aggregate purchase price of $45,850 pursuant to a Securities Purchase Agreement (the "SPA") dated February 28, 2024. The SPA also provides for a concurrent private placement of warrants to purchase common shares (the "Private Placement Warrants") . The Private Placement Warrants are exercisable immediately upon issuance until the earlier of (x) three and one-half years after the date of issuance, and (y) 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA in a Day 74 Letter or equivalent correspondence. F2 · balance_after: This number reflects a decrease of ownership of 6 shares of common stock from the number of shares previously reported due to an administrative error at the time of the Issuer's 1-for-20 split on July 31, 2020. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 23:54 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-24-002192 · doc4.xml · derivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-01-22 F3 · derivative.exercise_date: The options vest one-third on the first anniversary of January 22, 2024 and thereafter in monthly installments over 24 months. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 23:54 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantPerformance Restricted Stock Unit (PRSU) · Derivative | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002192 · doc4.xml · derivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-01-22 F1 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F2 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones being met. The PRSUs will lapse in full if achievement of at least one of the milestones is not met. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:42 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | PurchaseCommon Stock | 5,000 | $5.50 | $27,500.00 |
DisclosureSEC source: 0001209191-23-033392 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,730 F1 · shares: The shares reported on this Form 4 were purchased in a registered direct offering at a price of $5.50 per share, for an aggregate purchase price of $27,500, pursuant to a Securities Purchase Agreement dated May 25, 2023. Read SEC document |
| April 28, 2023 Filed May 1, 2023 21:53 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionPerformance Restricted Stock Unit (PRSU) · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026319 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2025-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the PRSU 50% of the total shares underlying the PRSU vest on the achievement of a performance-based milestone, and 50% vest on the first anniversary of the achievement of such milestone. Read SEC document |
| April 28, 2023 Filed May 1, 2023 21:53 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 1,827 | $8.29 | $15,145.83 |
DisclosureSEC source: 0001209191-23-026319 · doc4.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,730 F2 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of PRSUs. Read SEC document |
| April 28, 2023 Filed May 1, 2023 21:53 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026319 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 20:13 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionPerformance Restricted Stock Unit (PRSU) · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025380 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the PRSU 50% of the total shares underlying the PRSU vest on the achievement of a performance-based milestone, and 50% vest on the first anniversary of the achievement of such milestone. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 20:13 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 7,324 | $6.80 | $49,803.20 |
DisclosureSEC source: 0001209191-23-025380 · doc4.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,596 F2 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of PRSUs. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 20:13 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025380 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 20:28 UTC Amendment | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 5,863 | $6.80 | $39,868.40 |
DisclosureSEC source: 0001209191-23-025536 · doc4a.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,057 F1 · shares: This amended Form 4 is filed to correct an administrative error which applied additional taxes and misreported the number of shares of common stock withheld by the issuer to satisfy the tax liability in connection with the settlement of performance restricted stock units. 5,863 shares were withheld instead of 7,324. F2 · balance_after: The number of shares beneficially owned by the reporting person increased from 54,596 shares to 56,075 shares. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:46 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001209191-23-005282 · doc4.xml · derivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-25 F3 · derivative.exercise_date: The options vest one-third on the first anniversary of January 25, 2023 and thereafter in monthly installments over 24 months. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:46 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantPerformance Restricted Stock Unit (PRSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005282 · doc4.xml · derivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-12-31 F1 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F2 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the PRSU, the number of underlying shares of the Issuers common stock that may ultimately vest range from 0% to 100% of the number of PRSUs initially granted, subject to certain milestones being met during the measurement period that begins on January 3, 2023 and ends on December 31, 2025. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 19:27 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 11,000 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001209191-22-058064 · doc4.xml · derivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-11-18 F1 · price: The unregistered shares reported on this Form 4 were purchased in a private placement as part of a unit. Each unit consists of (i) two shares of the Issuer's common stock, and (ii) a warrant to purchase one share of common stock, at a purchase price of $4.625 per unit. The warrants are exercisable at a price per share of common stock of $4.50. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 19:27 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | PurchaseCommon Stock | 22,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-058064 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,920 F1 · shares: The unregistered shares reported on this Form 4 were purchased in a private placement as part of a unit. Each unit consists of (i) two shares of the Issuer's common stock, and (ii) a warrant to purchase one share of common stock, at a purchase price of $4.625 per unit. The warrants are exercisable at a price per share of common stock of $4.50. F1 · price: The unregistered shares reported on this Form 4 were purchased in a private placement as part of a unit. Each unit consists of (i) two shares of the Issuer's common stock, and (ii) a warrant to purchase one share of common stock, at a purchase price of $4.625 per unit. The warrants are exercisable at a price per share of common stock of $4.50. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 20:39 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantCommon Stock | 3,059 | $4.37 | $13,367.83 |
DisclosureSEC source: 0001209191-22-046649 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,920 F1 · kind: Represents shares of common stock acquired under the Issuer's 2017 Employee Stock Purchase Plan. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 20:39 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionPerformance Restricted Stock Unit (PRSU) · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026273 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2025-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the PRSU 50% of the total shares underlying the PRSU vest on the achievement of a performance-based milestone, and 50% vest on the first anniversary of the achievement of such milestone. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 20:39 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 1,827 | $7.43 | $13,574.61 |
DisclosureSEC source: 0001209191-22-026273 · doc4.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,861 F2 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of PRSUs. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 20:39 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026273 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001209191-22-001671 · doc4.xml · derivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: The options vest one-third on the first anniversary of January 3, 2022 and thereafter in monthly installments over 24 months. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantPerformance Restricted Stock Unit (PRSU) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001671 · doc4.xml · derivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-01-03 F1 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F2 · derivative.exercise_date: Pursuant to the terms of the PRSU 50% of the total shares underlying the PRSU vest on the achievement of a performance-based milestone, and 50% vest on the first anniversary of the achievement of such milestone. The PRSUs will lapse in full if achievement of such milestone is not met. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:11 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 68 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-052578 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68 shares Expires 2021-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 1, 2017 and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:11 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 21 | $6.81 | $143.01 |
DisclosureSEC source: 0001209191-21-052578 · doc4.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,188 F2 · shares: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:11 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 68 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-052578 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Read SEC document |
| May 27, 2021 Filed May 27, 2021 20:10 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | PurchaseCommon Stock | 6,000 | $7.00 | $42,000.00 |
DisclosureSEC source: 0001209191-21-036229 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,141 F1 · shares: The shares reported on this Form 4 were purchased in an underwritten public offering of the Issuer's common stock and are subject to a lock-up agreement between the reporting person and Oppenheimer & Co. Inc., pursuant to which the shares cannot be sold for 90 days following May 25, 2021. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:24 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001209191-21-005879 · doc4.xml · derivative · entry 2 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-01-26 F3 · derivative.exercise_date: The options vest 25% on the first anniversary of January 26, 2021 and thereafter in monthly installments over 36 months. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:24 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantPerformance Restricted Stock Unit (PRSU) · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005879 · doc4.xml · derivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-01-26 F1 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F2 · derivative.exercise_date: Pursuant to the terms of the PRSU 50% of the total shares underlying the PRSU vest on the achievement of a performance-based milestone, and 50% vest on the first anniversary of the achievement of such milestone. The PRSUs will lapse in full if achievement of such milestone is not met. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:35 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001209191-20-059123 · doc4.xml · derivative · entry 1 Bencich John · CIK 0001477056 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-11-16 F1 · derivative.exercise_date: Pursuant to the terms of the options 50% of the total shares underlying the option vest on the achievement of a performance-based milestone, and 50% vest on the first anniversary of the achievement of such milestone. The options will lapse in full if achievement of such milestone is not met. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:26 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 69 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047495 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68 Underlying: Common Stock · 69 shares Expires 2021-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. F5 · shares: This RSU was initially reported as covering 54,800 shares and was adjusted on May 23, 2018 to reflect a 1-for-10 split, and which number has been adjusted to reflect the Stock Split. F6 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 1, 2017 and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:26 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 33 | $8.95 | $295.35 |
DisclosureSEC source: 0001209191-20-047495 · doc4.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141 F3 · shares: Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:26 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 69 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047495 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. F2 · balance_after: On July 31, 2020, the Issuer effected a 1-for-20 split of its common stock (the "Stock Split") resulting in a decrease of the reporting person's ownership by 1,996 shares of common stock. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:12 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-005584 · doc4.xml · derivative · entry 1 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-01-28 F1 · derivative.exercise_date: The options vest 25% on the first anniversary of January 28, 2020 and thereafter in monthly installments over 36 months. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 21:10 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-046185 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,740 Underlying: Common Stock · 1,370 shares Expires 2021-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 1, 2017 and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 21:10 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 408 | $1.88 | $767.04 |
DisclosureSEC source: 0001209191-19-046185 · doc4.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,101 F2 · shares: Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the reporting person. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 21:10 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-046185 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 21:33 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001209191-19-006155 · doc4.xml · derivative · entry 2 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-01-29 F2 · derivative.exercise_date: Pursuant to the terms of the options 25% of the total shares underlying the option vest on the achievement of a performance-based milestone, and 75% vest in monthly installments over 24 months commencing one month from achievement of such milestone. The options will lapse in full if achievement of such milestone is not met by mid-2019 Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 21:33 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001209191-19-006155 · doc4.xml · derivative · entry 1 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-29 F1 · derivative.exercise_date: The options vest 25% on the first anniversary of January 29, 2019 and thereafter in monthly installments over 36 months. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 22:30 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004316 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015 and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 22:30 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Tax withholdingCommon Stock | 9 | $1.16 | $10.44 |
DisclosureSEC source: 0001209191-19-004316 · doc4.xml · nonDerivative · entry 2 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,139 F2 · shares: Represents shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 22:30 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004316 · doc4.xml · nonDerivative · entry 1 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:36 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001209191-18-051894 · doc4.xml · derivative · entry 1 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: The options vest in monthly installments over 48 months commencing one month from September 20 2018. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 20:52 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046834 · doc4.xml · derivative · entry 5 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28 Underlying: Common Stock · 28 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock at settlement. F11 · shares: This RSU was previously reported as covering 568 shares, which number was adjusted to reflect the Stock Split. F12 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015 and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 20:52 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 45 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046834 · doc4.xml · derivative · entry 4 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock at settlement. F8 · shares: This RSU was previously reported as covering 909 shares, which number was adjusted to reflect the Stock Split. F9 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 12, 2014 and (ii) the first day thereafter during which the issuer's trading window is open. F10 · derivative.expiration_date: The RSUs expire 30 days from the date they vest. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 20:52 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046834 · doc4.xml · derivative · entry 3 Bencich John · CIK 0001477056 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,110 Underlying: Common Stock · 1,370 shares Expires 2021-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock at settlement. F6 · shares: This RSU was previously reported as covering 54,800 shares, which number was adjusted to reflect the Stock Split. F7 · derivative.exercise_date: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 1, 2017 and (ii) the first day thereafter during which the issuer's trading window is open. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.